Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > We were counted as down and out 8 months ago, we were never

<< Previous

Bullboard Posts

Next >>

Comment by 011Pekingon Mar 03, 2021 3:27pm

143 Views

Post# 32707307

RE:RE:RE:RE:RE:RE:RE:RE:We were counted as down and out 8 months ago, we were never

If you're talking to me you're lost. Ive been in this for 1.5years with 600k shares.

My question had nothing to do with what you're talking about but lest just forget about it. We're both here to make some money. I just wrote a question lol. Nothing to be angry about lol

<< Previous

Bullboard Posts

Next >>

Opawica seeks drill permits for Bazooka Gold Targets in Abitibi